20th annual European Pharmaceutical Pricing and Reimbursement
13 Oct 2014 - 14 Oct 2014 - London, UK
Market access remains one of the most significant current and future challenges for the industry. Spiralling drug development costs exert pressure to ensure successful and effective planning of your access strategies. With up to $5 billion in R&D costs for every successful drug launched, winning strategies are critical. Now in its 20th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time. Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia, including: GSK, Ministry of Health (Germany), Novartis, Gilead, National Pharmacy Association, Ipsen and many more - will thoroughly explain and offer advice on P&R and market access. The 2014 agenda will focus on case studies as applied to different countries and environments in terms of market access.